

Form PTO 1390 U.S. DEPARTMENT OF COM (REV 5-93)	NT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER P50464-1					
TRANSMITTAL LETTER T DESIGNATED / ELECTE CONCERNING A FILING	U.S. APPLICATION 10 11 42 9 8 3					
INTERNATIONAL APPLICATION NO. PCT/US97/04876	INTERNATIONAL FILING DATE 26 March 1997	PRIORITY DATE CLAIMED  26 March 1996				
TITLE OF INVENTION PLA2 INHIBITORS OF ANGIOGENESIS						
APPLICANT(S) FOR DO/EO/US  Jeffrey R. JACKSON and James D. WINKLER						
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and						

other information:

l	[x]	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2.	[]	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3.	[x]	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
1.	[x]	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.	[x]	A copy of the International Application as filed (35 U.S.C. 371(c)(2))
		<ul><li>a. [] is transmitted herewith (required only if not transmitted by the International Bureau).</li><li>b. [] has been transmitted by the International Bureau.</li></ul>
		c. [x] is not required, as the application was filed in the United States Receiving Office (RO/US).
5.	[]	A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7.	[]	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))  a. [] are transmitted herewith (required only if not transmitted by the International Bureau).  b. [] have been transmitted by the International Bureau.
		<ul><li>c. [] have not been made; however, the time limit for making such amendments has NOT expired.</li><li>d. [] have not been made and will not be made.</li></ul>
3.	[]	A translation of the amendments to the claims under PCT Article 19 (35 U.S. C. 371(c)(3)).
€.	[x]	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

## Items 11. to 16. below concern other document(s) or information included:

- 11. [x] An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
- 12. [] An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.

10. [] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35

- 13. [x] A FIRST preliminary amendment.
  - [ ] A SECOND or SUBSEQUENT preliminary amendment.
- 14. [] A substitute specification.

U.S.C. 371(c)(5)).

- 15. [] A change of power of attorney and/or address letter.
- 16. [] Other items or information:

				<u> </u>	
US APPLICATION NO. (if known see 37 5-12 1.50) INTERNATIONAL APPLICATION NO. PCT/US97/04876				ATTORNEYS DOCKET NO. P50464-1	
	ollowing fees are submit	CALCULATIONS	PTO USE ONLY		
Basi	ic National Fee (37 C.F.				
Search Rep	oort has been prepared by				
	al Preliminary Examinat				
but internat	tional Preliminary Exami tional search fee paid to				
			\$790.00		
	ernational Preliminary E				
	al search fee (37 CFR 1.4 al Preliminary Examinat			-	
	atisfied provisions of PC		•		•
			SIC FEE AMOUNT =	\$98.00	
	30.00 for furnishing the earliest claimed priority	\$0.00			
Claims		Number Extra	Rate		
Total claims	6-20	0	0 x \$22.00	\$0.00	
Independent claims	1-3=	0	0 x \$82.00	\$0.00	
Multiple depend	dent claims (if applicable	)	+ \$270.00	\$0.00	
		\$98.00	!		
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).			\$		
		<del></del>	SUBTOTAL =	\$98.00	
	of \$130.00 for furnishing as from the earliest claim			\$	
		\$98.00			
				Amount to be refunded	\$
				charged	\$

- a. A check in the amount of <u>\$</u> to cover the above fees is enclosed.
- b. Please charge my Deposit Account No. <u>19-2570</u> in the amount of <u>\$98.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-2570</u>. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO: SMITHKLINE BEECHAM CORPORATION Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5017 Facsimile (610) 270-5090

**SIGNATURE** 

Dara L. Dinner

**NAME** 

33,680

REGISTRATION NO.

n:\dld\patents\p50464-1.doc

## 404 Rec'd PCT/P 1 8 SEP 1998 09/142983

PATENT ATTORNEY'S DOCKET NUMBER <u>**P50464-1**</u>

## TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

26 MARCH 1997

TITLE OF INVENTION
PLA2 INHIBITORS OF ANGIOGENESIS

APPLICANT(S) FOR DO/US
Jeffrey R. JACKSON and James D. WINKLER

Box PCT
Commissioner of Patents and Trademarks
Washington, D.C. 20231
ATTENTION: DO/US

## **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this Transmittal Letter and the papers indicated as being transmitted therewith is being deposited with the United States Postal Service on this date **September 18, 1998** in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number **EL085632941US** addressed to the: Assistant Commissioner of Patents, Washington, D.C. 20231.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper)